The DESCAR-T registry was set up at the request of health authorities to improve knowledge about CAR-T cell therapies marketed in France for treating patients with malignant hematology. The objective of this register is to support data on the short- and long-term efficacy and tolerance of these treatments in real life.
Using the data collected, the registry allows projects to be conducted to answer specific research questions. One of these projects focuses on the impact of CAR-T administration timing on prognosis and efficacy in the treatment of hematologic malignancies such as lymphomas, acute lymphoblastic leukemias, and myelomas.
Why is this study implemented?
The circadian rhythm impacts most biological systems, but also tumor proliferation and tumor circulation. Understanding the genomic and molecular mechanisms underlying the control of this cycle was rewarded with the Nobel Prize in Medicine in 2017.
The impact of administration schedule on cytotoxic efficacy and toxicity has been demonstrated in positive international randomized trials. There are strong arguments for the impact of administration schedule for retrospective and prospective immunotherapies.
There is currently no data on the impact of administration schedule on CART efficacy and toxicities.
What are the objectives of the Chrono CAR-T study?
The hypothesis of the “Chrono CAR-T” research project is that the timing of CAR-T cell administration has an impact on prognosis and efficacy in the treatment of blood diseases such as lymphomas, acute lymphoblastic leukemias, and myelomas.
This study is being conducted to test this hypothesis in a large population of patients treated with CAR-T cells in a real-world setting.
How will this study be conducted?
This study is based on the analysis of data from the medical records of patients participating in DESCAR-T. These analyses will be carried out by the project leader with the assistance of the LYSARC teams.
This study is being conducted by Dr. Boris DUCHEMANN of AP-HP HUPSSD – Sorbonne Paris Nord University (Assistance Publique des Hôpitaux de Paris) and by its two co-leaders François LEMONNIER (AP-AP – Henri-Mondor) and Sylvain CHOQUET (AP-HP – la Pitié Salpêtrière), both members of LYSA.
They will have access to data on all patients participating in the DESCAR-T study. It will not be possible to establish a link between the data and the identity of the patients because data are pseudonymized: the name and surname of each person are replaced by a unique number assigned at inclusion in DESCAR-T. LYSARC and its partners cannot link this number to a patient’s identity.
Study “Chrono CAR-T” is scheduled to begin in October 2025.
FOR PATIENTS PARTICIPATING IN DESCAR-T
What does this study mean for you?
This study is only for patients participating in DESCAR-T (all pathologies combined) who have received treatment with CAR-T (Chimeric Antigen Receptor T) cells or CAR-T cells.
If you are in this situation and you agree that your data be used for this study, this has no direct implication for you.
In particular, you will not have to answer any additional questionnaire compared to what is already planned as part of your participation in DESCAR-T.
What should you do about this study?
There are two options:
You are not opposed to the use of your data in the context of this study:
=> in this case, you do not have to do anything
- You wish to object to the use of your data in the context of this study:
⇒ in this case, you must inform the doctor who suggested you participate in the DESCAR-T study. You can also notify your decision by email at : dpo@lysarc.org.
You will find detailed information about your rights to object to the use of your data in the information provided to you when you agreed to participate in DESCAR-T.